148186 20250114175434.0 doi 10.1210/clinem/dgac412 sideral 130347 ART-2022-130347 eng Ramos-Caceres, Maria Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration 2022 Background Lipoprotein(a) (Lp(a)) is a significant cardiovascular risk factor. Knowing the mechanisms that regulate its concentration can facilitate the development of Lp(a)-lowering drugs. This study analyzes the relationship between triglycerides (TGs) and Lp(a) concentrations, cross-sectionally and longitudinally, and the influence of the number and composition of TG-rich lipoproteins, and the APOE genotype. Methods Data from Aragon Workers Health Study (AWHS) (n = 5467), National Health and Nutrition Examination Survey III phase 2 (n = 3860), and Hospital Universitario Miguel Servet (HUMS) (n = 2079) were used for cross-sectional TG and Lp(a) relationship. Lp(a) intrasubject variation was studied in AWHS participants and HUMS patients with repeated measurements. TG-rich lipoproteins were quantified by nuclear magnetic resonance in a subsample from AWHS. Apolipoproteins B and E were quantified by Luminex in very low-density lipoprotein (VLDL) isolated by ultracentrifugation, from HUMS samples. APOE genotyping was carried in AWHS and HUMS participants. Regression models adjusted for age and sex were used to study the association. Results The 3 studies showed an inverse relationship between TG and Lp(a). Increased VLDL number, size, and TG content were associated with significantly lower Lp(a). There was an inverse association between the apoE concentration in VLDL and Lp(a). No significant association was observed for apolipoprotein (apo)B. Subjects carrying the apoE2/E2 genotype had significantly lower levels of Lp(a). Conclusion Our results show an inverse relationship Lp(a)-TG. Subjects with larger VLDL size have lower Lp(a), and lower values of Lp(a) were present in patients with apoE-rich VLDL and apoE2/E2 subjects. Our results suggest that bigger VLDLs and VLDLs enriched in apoE are inversely involved in Lp(a) plasma concentration. Access copy available to the general public Unrestricted info:eu-repo/grantAgreement/ES/DGA/B14-7R info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI19-00694 info:eu-repo/grantAgreement/ES/MINECO/PI18-01777 info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 5.8 2022 ENDOCRINOLOGY & METABOLISM 31 / 144 = 0.215 2022 Q1 T1 1.776 2022 Biochemistry 2022 Q1 Biochemistry (medical) 2022 Q1 Medicine (miscellaneous) 2022 Q1 Endocrinology 2022 Q1 Endocrinology, Diabetes and Metabolism 2022 Q1 Clinical Biochemistry 2022 Q1 9.9 2022 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Lamiquiz-Moneo, Itziar Universidad de Zaragoza (orcid)0000-0002-9647-0108 Cenarro, Ana Calmarza, Pilar Marco-Benedi, Victoria Bea, Ana M. Mateo-Gallego, Rocio Universidad de Zaragoza (orcid)0000-0001-6650-8294 Puzo, Jose Universidad de Zaragoza (orcid)0000-0002-1309-4363 Ordovas, Jose M. Civeira, Fernando Universidad de Zaragoza (orcid)0000-0001-7043-0952 Laclaustra, Martin Universidad de Zaragoza (orcid)0000-0003-3963-0846 1006 255 Universidad de Zaragoza Dpto. Fisiatría y Enfermería Área Enfermería 1003 027 Universidad de Zaragoza Dpto. Anatom.Histolog.Humanas Area Anatom.Embriol.Humana 1007 610 Universidad de Zaragoza Dpto. Medicina, Psiqu. y Derm. Area Medicina 107, 9 (2022), E3594-E3602 J. clin. endocrinol. metab. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 0021-972X 355187 http://zaguan.unizar.es/record/148186/files/texto_completo.pdf Versión publicada 507687 http://zaguan.unizar.es/record/148186/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:148186 articulos driver 2025-01-14-15:49:05 ARTICLE